Since higher-dose formulations of oral and subcutaneous semaglutide are under development, it needs to be seen if they will be approved as anti-obesity drugs [34]
Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, et al
I ate real, whole foodsincluding dairy and legumes
Higher concentrations reduce injection volume but require more precise measurement
Mistake 3: injecting too fast Subcutaneous injections should be slow
However, meaningful, clinically significant weight loss typically defined as 5% of baseline body weight, a threshold referenced in NICE guidance on the management of overweight and obesity generally becomes apparent between weeks 8 and 12 , particularly as the dose is gradually escalated according to the trial protocol